Search

Your search keyword '"Gayther, SA"' showing total 284 results

Search Constraints

Start Over You searched for: Author "Gayther, SA" Remove constraint Author: "Gayther, SA" Search Limiters Full Text Remove constraint Search Limiters: Full Text
284 results on '"Gayther, SA"'

Search Results

1. Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility "hot-spot".

2. Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer

3. Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium.

4. Concurrent RB1 loss and BRCA-deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma.

5. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

6. Lifetime ovulatory years and risk of epithelial ovarian cancer: a multinational pooled analysis

7. Profiling the immune landscape in mucinous ovarian carcinoma

8. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

9. A multi-level investigation of the genetic relationship between endometriosis and ovarian cancer histotypes

10. Polygenic risk modeling for prediction of epithelial ovarian cancer risk (vol 30, pg 349, 2021)

11. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

12. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

13. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

14. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas

15. The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant

16. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (vol 12, 1078, 2021)

17. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

18. Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers.

19. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

21. Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D

22. Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers

23. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

24. Prognostic gene expression signature for high-grade serous ovarian cancer

25. Shared heritability and functional enrichment across six solid cancers

26. The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

27. Shared heritability and functional enrichment across six solid cancers (vol 10, 431, 2019)

28. A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants

29. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

30. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

31. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study

32. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium

33. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

34. Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction

35. Use of common analgesic medications and ovarian cancer survival: Results from a pooled analysis in the Ovarian Cancer Association Consortium

36. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci

37. Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

38. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies

39. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

40. Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer

41. Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci

42. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer

43. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer

44. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus

45. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

46. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

47. Risk of ovarian cancer and the NF-kB pathway: Genetic association with IL1A and TNFSF10

48. Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer

49. Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk

50. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk

Catalog

Books, media, physical & digital resources